NEW YORK – Myriad Genetics said Thursday that it has completed the sale of its EndoPredict breast cancer prognostic test business to Eurobio Scientific for an undisclosed amount.
As part of the sale, it granted France-based Eurobio the rights to sell in vitro diagnostic kits for its Prolaris prostate cancer prognostic test outside the US.
Myriad retained the rights to produce and sell EndoPredict in the US as part of its Precise Oncology Solutions platform.
Salt Lake City-based Myriad announced the sale of EndoPredict in May as part of a reorganization of its international operations.
Myriad partnered with Intermountain Precision Genomics last year to develop Precise Oncology Solutions, which comprise Myriad's MyRisk Hereditary Cancer test and MyChoice CDx as well as Intermountain's TheraMap tumor profiling test.
"The reorganization of Myriad's international operations will enable us to continue growing our oncology and biopharma business in Europe and Asia, including Japan, through a more efficient commercial distribution model that reduces organizational complexity and enterprise risk," Paul Diaz, president and CEO of Myriad, said in a statement.